期刊文献+

二甲双胍联合沙格列汀治疗2型糖尿病的临床效果分析 被引量:1

Clinical Effect of Metformin Combined With Saxagliptin in the Treatment of Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的探讨二甲双胍联合沙格列汀治疗2型糖尿病的临床效果。方法选取我院收治的82例2型糖尿病患者为研究对象,将其分为对照组(41例)与观察组(41例)。对照组给予二甲双胍口服治疗,观察组在此基础上,联合沙格列汀治疗,观察两组效果。结果观察组血糖指标的控制情况优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论二甲双胍联合沙格列汀治疗2型糖尿病效果显著,可有效控制患者血糖指标。 Objective To explore the clinical effect of metformin combined withsaxagliptin in the treatment of type 2 diabetes mellitus. Methods 82 casesof patients with type 2 diabetes mellitus in our hospital were selected as the research objects, and they were divided into control group(41 cases) and observation group(41 cases). The control group was treated with metformin orally, the observation group, on this basis of the treatment methods of control group, combined with saxagliptin treatment, to observe the effect of the two groups. Results The control of blood glucose in the observation group was significantly better than that in the control group, the difference was statistically significant(P 〈 0.05); The incidence of adverse reactions in the two groups had no significant difference(P 〉 0.05). Conclusion Metformin combined with saxagliptin in the treatment of type 2 diabetes has significant effect, which can effectively control blood glucose indicators.
作者 赵健
出处 《中国继续医学教育》 2017年第27期96-97,共2页 China Continuing Medical Education
关键词 二甲双胍 沙格列汀 2型糖尿病 血糖指标 metformin saxagliptin type 2 diabetes mellitus blood glucose index
  • 相关文献

参考文献8

二级参考文献68

  • 1中华医学会糖尿病学分会_中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志:电子版,2011,3(6):54-109.
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中华糖尿病杂志,2010,2增刊2:1-56.
  • 3Nathan DM, Buse JB, Davidson MB, et al. Medical managemen! of hyperglycenfia in type 2 diabetes: a consensus algorithm for the initiation and adjustmenl of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [ J ]. Diabetes Care,2009,32 ( 1 ) :193-203.
  • 4Danaei G,Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of heahh examination surveys and epidemiological studies with 370 country-years and 2.7 million participants [ J ]. Lancet,2011,378 ( 9785 ) :31-40.
  • 5Goldnmn-Levine JD. Beyond methrmin: initiating combination therapy in patients with type 2 diabetes mellitus [ J ]. Pharma- cotherapy,2011,31 ( 12 Suppl) :44S-53S.
  • 6Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus [J]. Pharmacotherapy,2010,30(5 ) :463-484.
  • 7Jadzinsky M, Pftitzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with meffornain as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial [ J ]. Diabetes Obes Metab,2009,11 (6) :611-622.
  • 8Gke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone : a 52-week randomised controlled trial [ J ]. Int J Clin Pract ,2010,64 (12) : 1619-1631.
  • 9DeFronzo RA, Hissa MN, Garber A J, et al. The efficacy and safety of saxagliptin when added to metfmanin therapy in patients with inadequately controlled type 2 diabetes with rnetformin alone [ J ]. Diabetes Care, 2009,32 ( 9 ) : 1649 -I 655.
  • 10Fonseca V,Zhu T, Karyekar C, et al, Adding saxagliptin to extended- release metformin vs. uptitrating metformin dosage [ J ]. Diabetes Obes Metab,2012,14(4) :365-371.

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部